Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

References

• Alexander DJ, Collins CJ, Coombs DW, et al. (2008). Association of Inhalation Toxicologists (AIT) Working Party Recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol 20:1179–89.
   PubMed Web of Science ®Google Scholar
• Allen JW, Moon J, Redman M, et al. (2014). Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463–70.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Grimes MJ, Picchi MA, et al. (2011). Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 71:454–62.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–65.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Pao W, Sequist LV. (2014). Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473–81.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. (2017). First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–26.
   PubMed Web of Science ®Google Scholar
• Davis M, Li J, Knight E, et al. (2015). Toxicogenomics profiling of bone marrow from rats treated with topotecan in combination with oxaliplatin: a mechanistic strategy to inform combination toxicity. Front Genet 6:14.
   PubMed Web of Science ®Google Scholar
• Desai SD, Haas AL, Wood LM, et al. (2006). Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 66:921–8.
   PubMed Web of Science ®Google Scholar
• Desai SD, Wood LM, Tsai YC, et al. (2008). ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 7:1430–9.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Mahler DA, Sethi S. (2019). Revefenacin: a once-daily, long-acting bronchodilator for nebulized treatment of COPD. Int J Chron Obstruct Pulmon Dis 14:2947–58.
   PubMed Web of Science ®Google Scholar
• Eckardt JR, von Pawel J, Pujol JL, et al. (2007). Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–92.
   PubMed Web of Science ®Google Scholar
• Gabr A, Kuin A, Aalders M, et al. (1997). Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 57:4811–6.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–92.
   PubMed Web of Science ®Google Scholar
• Jones S, Thompson D, Barton J, et al. (2008). A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 9:154–9.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Kris MG, Smith IE, et al. (1998). Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol 21:438–41.
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Kleinerman ES. (2005). Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 116:458–63.
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Kleinerman ES, Waidrep C, et al. (2000). 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876–80.
   PubMed Web of Science ®Google Scholar
• Kuehl PJ, Grimes MJ, Dubose D, et al. (2018). Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Deliv 25:1127–36.
   PubMed Web of Science ®Google Scholar
• Kuehl PJ, Tellez CS, Grimes MJ, et al. (2020). 5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming. Br J Cancer 122:1194–204.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Jr., Kalish L, Strauss G, et al. (1994). Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347–52.
   PubMed Web of Science ®Google Scholar
• Mann M, Meyer RJ. (2018). Drug development for asthma and COPD: a regulatory perspective. Respir Care 63:797–817.
   PubMed Web of Science ®Google Scholar
• Martin P, Leighl NB, Tsao MS, et al. (2013). KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 8:530–42.
   PubMed Web of Science ®Google Scholar
• Masuda N, Matsui K, Negoro S, et al. (2010). Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. Clin Lung Cancer 11:271–9.
   PubMed Web of Science ®Google Scholar
• Meng X, Liu Y, Zhang J, et al. (2017). PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges. Cancer Lett 405:29–37.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Ciuleanu TE, Tsekov H, et al. (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–7.
   PubMed Web of Science ®Google Scholar
• O'Brien M, Eckardt J, Ramlau R. (2007). Recent advances with topotecan in the treatment of lung cancer. Oncologist 12:1194–204.
   PubMed Web of Science ®Google Scholar
• Otterson GA, Villalona-Calero MA, Sharma S, et al. (2007). Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 13:1246–52.
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–500.
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175–80.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Fossella FV, Glisson BS, et al. (1996). Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503–13.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. (2020). Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383:35–48.
   PubMed Web of Science ®Google Scholar
• Ramlau R, Gervais R, Krzakowski M, et al. (2006). Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24:2800–7.
   PubMed Web of Science ®Google Scholar
• Reed MD, Tellez CS, Grimes MJ, et al. (2013). Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 109:1775–81.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. (2018). Cancer immunotherapy using checkpoint blockade. Science 359:1350–5.
   PubMed Web of Science ®Google Scholar
• Sharma V, McNeill JH. (2009). To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–21.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2020). Cancer statistics, 2020. CA A Cancer J Clin 70:7–30.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. (2018). Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–301.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–6.
   PubMed Web of Science ®Google Scholar
• Tessema M, Klinge DM, Yingling CM, et al. (2010). Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29:5159–70.
   PubMed Web of Science ®Google Scholar
• Tessema M, Yingling CM, Thomas CL, et al. (2012). SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31:4107–16.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, et al. (2005). Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 353:133–44.
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Simanek EE. (2010). Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 7:307–49.
   PubMed Web of Science ®Google Scholar
• Verco J, Johnston W, Baltezor M, et al. (2019). Pharmacokinetic profile of inhaled submicron particle paclitaxel (NanoPac®) in a rodent model. J Aerosol Med Pulm Drug Deliv 32:99–109.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Gilbert BE, Loyer E, et al. (2004). Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10:2319–26.
   PubMed Web of Science ®Google Scholar
• Voelker R. (2020). Generic albuterol inhaler approved. JAMA 323:1887.
   Web of Science ®Google Scholar
• von Pawel J, Jotte R, Spigel DR, et al. (2014). Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32:4012–9.
   PubMed Web of Science ®Google Scholar
• Wang C, Qiao W, Jiang Y, et al. (2020). The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cell Physiol 235:4913–27.
   PubMed Web of Science ®Google Scholar
• Weitz JJ, Marschke RF, Jr., Sloan JA, et al. (2000). A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28:157–62.
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924–37.
   PubMed Web of Science ®Google Scholar
• Wittgen BP, Kunst PW, van der Born K, et al. (2007). Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 13:2414–21.
   PubMed Web of Science ®Google Scholar